Two different pharmacophoric domains attached covalently by a linker domain. Two different pharmacophoric domains attached covalently by a linker domain. The lability of the linker determines the type of antibiotic hybrid generated. A linker that can be enzymatically degraded (preferably by only bacterium-specific enzymes) gives rise to two functional pharmacophoric entities that are thus used in the antibiotic hybrid prodrug strategy. A linker that is inert to enzymatic degradation is used to hold the two pharmacophoric domains together in the antibiotic hybrid drug strategy. Ronald Domalaon et al. Clin. Microbiol. Rev. 2018; doi:10.1128/CMR.00077-17